Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.

Author(s): Hari Kumar KV(1), Shaikh A, Prusty P.

Affiliation(s): Author information: (1)Department of Endocrinology, Command Hospital, Lucknow 226002 Uttar Pradesh, India. hariendo@rediffmail.com

Publication date & source: 2013, Diabetes Res Clin Pract. , 100(2):e55-8

Incretin based therapies are known to have pleotropic benefits in type 2 diabetes but have not been studied in new onset type 1 diabetes. In this randomized, open label study, we investigated the effect of the addition of exenatide or sitagliptin to insulin in patients with new onset type 1 diabetes. Our data suggest that the addition of exenatide and sitagliptin decreases insulin requirements without increasing endogenous insulin production and hypoglycemic events.